2020
Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis
Jiang R, Hoehn KB, Lee CS, Pham MC, Homer RJ, Detterbeck FC, Aban I, Jacobson L, Vincent A, Nowak RJ, Kaminski HJ, Kleinstein SH, O'Connor KC. Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 30649-30660. PMID: 33199596, PMCID: PMC7720237, DOI: 10.1073/pnas.2007206117.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAutoantibodiesB-LymphocytesBiomarkersClonal EvolutionClonal Selection, Antigen-MediatedDisease SusceptibilityFemaleHumansLymphocyte CountMaleMiddle AgedModels, BiologicalMyasthenia GravisRadioimmunoassayReceptors, CholinergicThymectomyThymus GlandV(D)J RecombinationYoung AdultConceptsB cell clonesMyasthenia gravisB cell repertoireB cellsCell clonesPlasma cellsCell repertoireAdditional immunosuppressive treatmentDiminished clinical responseThymic lymphofollicular hyperplasiaComplete stable remissionMajority of patientsAntigen-experienced B cellsRandomized clinical trialsClinical symptom measuresAChR autoantibodiesImmunosuppressive treatmentSteroid doseAutoantibody titersMG thymusClinical responseStable remissionClinical scoresAutoimmune diseasesClinical trials
2019
A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases
Zhao J, Bhatnagar V, Ding L, Atay SM, David EA, McFadden PM, Stamnes S, Lechtholz-Zey E, Wightman SC, Detterbeck FC, Kim AW. A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases. Journal Of Thoracic And Cardiovascular Surgery 2019, 160: 306-314.e14. PMID: 31982129, DOI: 10.1016/j.jtcvs.2019.11.052.Peer-Reviewed Original ResearchReport from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours
Ruffini E, Guerrera F, Brunelli A, Passani S, Pellicano D, Thomas P, Van Raemdonck D, Rocco G, Venuta F, Weder W, Detterbeck F, Falcoz PE. Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours. European Journal Of Cardio-Thoracic Surgery 2019, 55: 601-609. PMID: 30649256, DOI: 10.1093/ejcts/ezy448.Peer-Reviewed Original ResearchConceptsNeuroendocrine thymic tumoursThymic tumorsAdjuvant treatmentThymic carcinomaStage IStage IIIB tumorsEuropean SocietyStage IV tumorsOverall recurrence rateInvasive surgical approachNew International AssociationCollaborative global effortIIIB tumorsProspective databaseStage IIIAMetastasis classificationRecurrence rateGroup tumorsRare tumorSurgical approachRetrospective databaseInvasive techniquesStage IIIPatientsTumors
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatientsDelayed discharge does not decrease the cost of readmission after pulmonary lobectomy
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD. Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy. Surgery 2018, 164: 1294-1299. PMID: 30064733, DOI: 10.1016/j.surg.2018.05.049.Peer-Reviewed Original ResearchConceptsRisk-adjusted readmission ratesReadmission ratesLate dischargeDischarge groupPulmonary lobectomyCostly readmissionsLung cancerHospital costsOverall health care utilizationExcess health care costsRoutine dischargeCosts of readmissionIndex hospital costsLate discharge groupRoutine discharge groupPatients 65 yearsNationwide Readmissions DatabaseHospital day 1Hospital day 4Health care utilizationCases of lobectomyHealth care costsIndex hospitalHospital durationCare utilizationIncorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement
Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS. Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2018, 198: e3-e13. PMID: 30004250, DOI: 10.1164/rccm.201805-0986st.Peer-Reviewed Original ResearchConceptsLung cancer screeningRisk of deathPatient selectionChronic illnessCancer screeningLung cancerOfficial American Thoracic Society Research StatementHarms of LCSImplementation of LCSScreen-detected lung cancersChronic obstructive pulmonary diseaseRisk of comorbiditiesObstructive pulmonary diseaseEffect of comorbidityLung cancer deathsTreatment-related harmsLung cancer riskBalance of benefitsPulmonary diseaseCancer deathBaseline riskCancer riskComorbiditiesHealthy individualsInternational cliniciansWhen good operations go bad: The additive effect of comorbidity and postoperative complications on readmission after pulmonary lobectomy
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Blasberg JD, Kim AW. When good operations go bad: The additive effect of comorbidity and postoperative complications on readmission after pulmonary lobectomy. Surgery 2018, 164: 294-299. PMID: 29801731, DOI: 10.1016/j.surg.2018.03.019.Peer-Reviewed Original ResearchConceptsPostoperative complicationsReadmission ratesPulmonary lobectomyAdditional comorbiditiesThoracic surgeryCause readmission rateDays of dischargeNationwide Readmissions DatabaseNumber of comorbiditiesRisk of readmissionMajor thoracic surgeryProbability of readmissionLow risk profileHealth care deliveryHospital factorsHospital readmissionLow comorbidityElixhauser comorbiditiesThoracic lobectomyLung cancerPrimary diagnosisChronic diseasesHigh burdenMean changeValue-based reimbursement
2017
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database
Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. Journal Of Thoracic Oncology 2017, 13: 436-446. PMID: 29191778, PMCID: PMC5983900, DOI: 10.1016/j.jtho.2017.11.118.Peer-Reviewed Original ResearchConceptsThymic epithelial tumorsIndependent prognostic factorOverall survivalPrognostic factorsPrognostic roleRetrospective databaseCox proportional hazards modelKaplan-Meier methodRecurrence-free survivalProportional hazards modelParaneoplastic syndromeCumulative incidenceResection statusTotal thymectomyMyasthenia gravisThymic malignanciesHistologic typeSyndrome statusFemale sexTreatment characteristicsEpithelial tumorsHazards modelLower CIRSyndromeMultivariate analysisIndications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT
Gao SJ, Kim AW, Puchalski JT, Bramley K, Detterbeck FC, Boffa DJ, Decker RH. Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT. Lung Cancer 2017, 109: 36-41. PMID: 28577947, DOI: 10.1016/j.lungcan.2017.04.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungClinical Decision-MakingDiagnostic ImagingFemaleHumansLung NeoplasmsMaleMediastinumMiddle AgedNeoplasm MetastasisNeoplasm StagingPatient SelectionPositron Emission Tomography Computed TomographyPractice Guidelines as TopicRetrospective StudiesConceptsOccult N2 diseaseOccult N2 metastasesGround-glass componentInvasive mediastinal stagingCurative-intent therapyT2 tumorsN2 metastasisPET-CTInvasive stagingN2 diseaseT1 tumorsNegative predictive valueMediastinal stagingEarly non-small cell lung cancerExact testPredictive valueSolid tumorsNon-small cell lung cancerClinical stage I NSCLCN2 lymph nodesNode-negative NSCLCOccult nodal involvementPure-solid tumorsStage I NSCLCT1-2N0 diseaseComparison of surgical approach and extent of resection for Masaoka-Koga Stage I and II thymic tumours in Europe, North America and Asia: an International Thymic Malignancy Interest Group retrospective database analysis†
Fang W, Yao X, Antonicelli A, Gu Z, Detterbeck F, Vallières E, Aye RW, Farivar AS, Huang J, Shang Y, Louie BE. Comparison of surgical approach and extent of resection for Masaoka-Koga Stage I and II thymic tumours in Europe, North America and Asia: an International Thymic Malignancy Interest Group retrospective database analysis†. European Journal Of Cardio-Thoracic Surgery 2017, 52: 26-32. PMID: 28329118, PMCID: PMC6279116, DOI: 10.1093/ejcts/ezx042.Peer-Reviewed Original ResearchConceptsExtent of resectionThymic tumorsStage IAsian patientsSurgical approachOnly independent predictive factorMasaoka-Koga stage IMore stage IOutcomes of patientsPathological stage IIndependent predictive factorsIndependent risk factorOverall survival rateCumulative recurrence rateSmaller tumor sizeRetrospective database analysisNorth American patientsPartial thymectomyAdjuvant therapyParaneoplastic syndromeThymic carcinomaOverall survivalPerformance statusComplete resectionMyasthenia gravis“What if I do nothing?” The natural history of operable cancer of the alimentary tract
Keshava HB, Rosen JE, DeLuzio MR, Kim AW, Detterbeck FC, Boffa DJ. “What if I do nothing?” The natural history of operable cancer of the alimentary tract. European Journal Of Surgical Oncology 2017, 43: 788-795. PMID: 28131669, DOI: 10.1016/j.ejso.2016.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Signet Ring CellCarcinoma, Squamous CellColonic NeoplasmsDatabases, FactualDisease ProgressionEsophageal NeoplasmsFemaleGastrointestinal NeoplasmsHumansMaleMiddle AgedNeoplasm StagingRectal NeoplasmsStomach NeoplasmsSurvival RateUnited StatesWatchful WaitingConceptsAlimentary tract cancersTract cancerNatural historyUntreated patientsCancer surgeryClinical stage IStage-specific survivalOperable cancerInoperable patientsMedian survivalRectal cancerClinical stagePreoperative counselingPatientsStage ISurgeryCancerPoor healthAlimentary tractSurvivalHealth reasonsStudy objectiveTreatmentCIICIII
2016
Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database
Rimner A, Yao X, Huang J, Antonicelli A, Ahmad U, Korst RJ, Detterbeck F, Gomez DR. Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database. Journal Of Thoracic Oncology 2016, 11: 1785-1792. PMID: 27346413, PMCID: PMC5257334, DOI: 10.1016/j.jtho.2016.06.011.Peer-Reviewed Original ResearchConceptsPostoperative radiation therapyStage IIOS benefitRadiation therapyUse of PORTMasaoka-Koga stage IIInternational Thymic Malignancy Interest GroupStage II thymomaOverall survival benefitPrimary end pointMultivariate Cox modelLonger overall survivalLog-rank testIndividual patient dataImproved OSParaneoplastic syndromeOverall survivalSurvival benefitOS ratesHistologic subtypePatient populationRetrospective databaseUnivariate analysisCox modelThymomaLung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. Journal Of Thoracic Oncology 2016, 11: 1121-1131. PMID: 27103511, DOI: 10.1016/j.jtho.2016.03.023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer Data BaseYounger patientsOlder patientsLung cancerRelative survivalStage IAdvanced stage non-small cell lung cancerCell lung cancerYears of ageAggressive therapyAggressive treatmentOverall survivalPatient demographicsPrimary outcomeTreatment patternsTumor characteristicsNSCLC casesPatientsStage IIIDetailed stagingSurvival informationOlder groupDistinct subsetsCancerComparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group†
Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, Guerrera F, Venuta F, van Raemdonck D, Travis W, Lucchi M, Rimner A, Thomas P, Weder W, Rocco G, Detterbeck F, Korst R. Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group†. European Journal Of Cardio-Thoracic Surgery 2016, 50: 766-771. PMID: 27032473, PMCID: PMC6279171, DOI: 10.1093/ejcts/ezw107.Peer-Reviewed Original ResearchConceptsNeuroendocrine thymic tumoursRecurrence-free survivalThymic carcinomaOverall survivalSurvival rateThymic tumorsThoracic surgeonsFive-year recurrence-free survivalWorld Health Organization histological classificationRetrospective multicentre cohort studyInternational Thymic Malignancy Interest GroupMedian overall survivalMulticentre cohort studyEuropean SocietyKaplan-Meier methodThymic epithelial tumorsLarge clinical seriesLog-rank testComparison of outcomesGroup of tumorsR0 resectionCohort studyPrognostic factorsNET patientsTC patientsAnalyzing Risk Factors for Morbidity and Mortality after Lung Resection for Lung Cancer Using the NSQIP Database
Jean RA, DeLuzio MR, Kraev AI, Wang G, Boffa DJ, Detterbeck FC, Wang Z, Kim AW. Analyzing Risk Factors for Morbidity and Mortality after Lung Resection for Lung Cancer Using the NSQIP Database. Journal Of The American College Of Surgeons 2016, 222: 992-1000.e1. PMID: 27118714, DOI: 10.1016/j.jamcollsurg.2016.02.020.Peer-Reviewed Original ResearchConceptsPreoperative risk factorsAnatomic pulmonary resectionMultivariate logistic regressionRisk factorsPreoperative dyspneaPulmonary resectionLogistic regressionNSQIP databaseMultivariate logistic regression modelingIntraoperative risk factorsRetrospective cohort studyDay of surgerySurgeons NSQIP databaseLogistic regression modelingLogistic regression modelsElective lobectomyPreoperative anemiaPerioperative complicationsPerioperative mortalityPostoperative complicationsLung resectionClinical factorsCohort studyMale sexOpen lobectomyDetection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)
Martin LW, D'Cunha J, Wang X, Herzan D, Gu L, Abraham N, Demmy TL, Detterbeck FC, Groth SS, Harpole DH, Krasna MJ, Kernstine K, Kohman LJ, Patterson GA, Sugarbaker DJ, Vollmer RT, Maddaus MA, Kratzke RA. Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). Journal Of Clinical Oncology 2016, 34: 1484-1491. PMID: 26926677, PMCID: PMC4872306, DOI: 10.1200/jco.2015.63.4543.Peer-Reviewed Original ResearchConceptsN2 lymph nodesStage I NSCLCDisease-free survivalOccult micrometastasesLymph nodesCell lung cancerOverall survivalLung cancerStage IClinical stage I NSCLCPathologic stage I NSCLCComplete surgical stagingClinical stage IRT-PCRDecreased overall survivalNegative lymph nodesWorse survival rateSquamous cell carcinomaReal-time reverse transcriptase-polymerase chain reactionMulti-institutional trialReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionWarrants further investigationSurgical stagingPrognostic significance
2015
Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm
Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Annals Of Surgical Oncology 2015, 23: 638-645. PMID: 26474557, DOI: 10.1245/s10434-015-4902-8.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyComorbidityFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPneumonectomyPrognosisSex FactorsSurvival RateYoung AdultConceptsNon-small cell lung cancerAdjuvant chemotherapyNational Cancer Data BaseNon-small cell lungCharlson-Deyo scorePretreatment prognostic factorsCell lung cancerCD scoresGroup of womenGroup of menConclusionsAdjuvant chemotherapySurvival benefitT2 tumorsPrognostic factorsDistant metastasisWomen 65Cell lungLung cancerNSCLC tumorsImproved outcomesChemotherapySurgeryPatientsWomenSurvivalMultimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database
Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F, Group E. Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database. Journal Of Thoracic And Cardiovascular Surgery 2015, 151: 47-57.e1. PMID: 26403869, DOI: 10.1016/j.jtcvs.2015.08.034.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAsiaChemotherapy, AdjuvantChi-Square DistributionChildDatabases, FactualDisease ProgressionDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNorth AmericaPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentRisk FactorsSocieties, MedicalThymectomyThymomaThymus NeoplasmsTime FactorsTreatment OutcomeTumor BurdenYoung AdultConceptsRelapse-free survivalAdvanced thymomaMultimodality therapyOverall survivalT classificationPropensity score-matched cohort studyMultivariate Cox proportional hazards modelPropensity score-matched analysisCox proportional hazards modelPathologic T classificationStage III thymomaThoracic Surgeons databaseSignificant survival advantageSpecific pathologic featuresStrong predictive factorProportional hazards modelInduction therapyAdjuvant therapyPT3 tumorsCohort studyIndependent predictorsPrognostic impactMultivariable analysisPathologic featuresPredictive factorsEvaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase
Liu J, Hancock JG, Moreno AC, Wang Z, Boffa DJ, Detterbeck FC, Kim AW. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase. European Journal Of Cardio-Thoracic Surgery 2015, 49: 596-601. PMID: 25890936, DOI: 10.1093/ejcts/ezv139.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsLymph NodesMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyRetrospective StudiesSurvival AnalysisTreatment OutcomeTumor BurdenUnited StatesConceptsPostoperative radiation therapyNational Cancer DatabaseNeoadjuvant chemoradiation therapyAdjuvant chemoradiation therapyChemoradiation therapyAdjuvant chemotherapyOverall survivalSurgical therapyLung cancerCancer DatabaseNode-negative lung cancerImproved OS relativeLymph node involvementKaplan-Meier methodCell lung cancerCox regression modelFate of patientsLog-rank testDifferent treatment modalitiesOS relativeNode involvementMetastatic diseaseSurgical resectionLymph nodesOS ratesBolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base
Combs SE, Hancock JG, Boffa DJ, Decker RH, Detterbeck FC, Kim AW. Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base. Journal Of Thoracic Oncology 2015, 10: 316-323. PMID: 25319182, DOI: 10.1097/jto.0000000000000402.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerNational Cancer Data BaseSurgical resectionStage ISCLC patientsSublobar resectionOverall survivalLung cancerIIIA small cell lung cancerFive-year overall survivalAddition of surgeryClinical stage IPatient underwent surgeryPrimary surgical resectionKaplan-Meier methodLikelihood of deathCurative intentComorbidity scoreUnderwent surgeryChemoradiation therapyHazard ratioMetastatic diseaseMultimodality treatmentSelect patientsTreatment regimen